← Back

GlucoTrack Inc

GlucoTrack, Inc., a medical device company, focuses on the development of an implantable continuous blood glucose monitor (CBGM) for people with diabetes in the United States. The company develops the GlucoTrack CBGM, a long-term implantable blood-based CBGM for use by Type 1 diabetes patients and insulin-dependent Type 2 diabetes patients. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Price · split & dividend adjusted
News & notes moving GCTK
Biotech & Genomic Medicine▲

Glucotrack, Bausch Health, Corcept Lead Biotech Surge on Pipeline and Earnings News

Glucotrack, Bausch Health, and Corcept Therapeutics were among Thursday's top biotech gainers, driven by pipeline progress and strong financial results. Glucotrack's subsidiary Lokahi Therapeutics advanced development of LT-100, a non-narcotic therapy derived from honeybee venom, with plans to begin clinical evaluation of a simplified single-injection method as early as the fourth quarter of 2026, sending shares up 173.68% to $0.78. Bausch Health raised its full-year 2026 revenue outlook to between $10.790 billion and $11.040 billion after reporting second-quarter consolidated revenue of $2.85 billion, a 13% increase, and its stock rose 28.85% to $6.03. Corcept Therapeutics posted second-quarter net income of $43.0 million on revenue of $256.1 million, including $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, and lifted its 2026 revenue forecast to $1.1 billion to $1.2 billion, pushing shares up 27.29% to $118.32. Nuwellis surged 135.45% to $4.45 after a study on its Aquadex therapy was accepted by a peer-reviewed journal, while Neogen touched a 52-week high of $11.56 and closed up 22.26% at $11.53 following its fiscal 2026 results and fiscal 2027 guidance.
BHC ▲CORT ▲GCTK ▲NEOG ▲NUWE ▲
Biotech & Genomic Medicine ▲
RTTNews·27dRead more ▾
GCTK2

E.F. Hutton Advises Glucotrack-Lōkahi Therapeutics Combination and Places $5.7 Million Financing

E.F. Hutton served as exclusive financial advisor on the strategic business combination between Glucotrack and Lōkahi Therapeutics and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million. The transaction creates a publicly traded healthcare platform combining Lōkahi Therapeutics' AI-driven asset sourcing with Glucotrack's Nasdaq listing, with Lōkahi becoming the operating and controlling business while Glucotrack's continuous blood glucose monitoring unit continues as a wholly owned subsidiary. The convertible note financing was placed with institutional investors, and net proceeds are expected to fund Lōkahi Therapeutics' post-closing operations and strategic initiatives. E.F. Hutton CEO Joseph T. Rallo stated the deal reflects the firm's commitment to guiding clients through strategic transactions and capital formation.
GCTK
GlobeNewswire·40dRead more ▾
GCTK

Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination

Glucotrack and Lōkahi Therapeutics have completed their strategic business combination, establishing a publicly listed platform controlled by Lōkahi. Under the deal, Lōkahi becomes the operating and controlling business, with its securityholders expected to hold approximately 90% of the combined company on a fully diluted basis upon conversion of preferred stock, subject to approvals and Nasdaq listing requirements. Erik Emerson has been appointed CEO of the combined company, while Paul Goode will serve as Chief Technical Officer and CEO of the CBGM subsidiary. Glucotrack's continuous blood glucose monitoring business will operate as a wholly owned subsidiary with separate operations and capital structure. A planned private placement financing will support the combined company's capital position, with a portion of proceeds allocated to the CBGM technology.
GCTK
GlobeNewswire·41dRead more ▾
Biotech & Genomic Medicine▲

Glucotrack Receives US Patent Allowance for Implantable Continuous Glucose Monitor

Glucotrack announced that the US Patent and Trademark Office issued a Notice of Allowance for a patent application covering its continuous blood glucose monitoring platform. The allowed patent expands intellectual property protection for the fully implantable system and includes electrode configurations, lead-based sensing structures, and associated implantation methods. This adds to three CBGM patents already issued in 2025. President and CEO Paul V. Goode stated that building intellectual property is fundamental to the company's strategy as it advances the system through clinical testing toward commercialization.
GCTK ▲
Biotech & Genomic Medicine
ExecEdge·49dRead more ▾
© 2026 MarketDXAsset